STING1 and autoimmune disease: Only a limited number of agents have advanced to clinical trials, including the endogenous-derived nitro fatty acid CXA-10 (NCT04053543, NCT04125745, NCT03449524), which has entered phase II studies for inflammatory and renal diseases, and VENT-03 (EUCT2023-507504-31-00) and IMSB-301 (ISRCTN90049550), first-in-class human STING modulators currently in phase I trials for autoimmune disorders.